A multicentre randomized phase III trial comparing pembrolizumab (P) vs single agent chemotherapy (CT) for advanced pre-treated malignant pleural mesothelioma (MPM): Results from the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial-Reference-Cited by-同舟云学术

A multicentre randomized phase III trial comparing pembrolizumab (P) vs single agent chemotherapy (CT) for advanced pre-treated malignant pleural mesothelioma (MPM): Results from the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial

Published:2019-10 Issue: Volume:30 Page:v931
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Popat S.,Curioni-Fontecedro A.,Polydoropoulou V.,Shah R.,O’Brien M.,Pope A.,Fisher P.,Spicer J.,Roy A.,Gilligan D.,Gautschi O.,Nadal E.,Janthur W.-D.,López Castro R.,García Campelo R.,Roschitzki-Voser H.,Ruepp B.,Rusakiewicz S.,Peters S.,Stahel R.A.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/30/Supplement_5/mdz394.091/30083399/mdz394.091.pdf

Cited by 32 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical case of using combination of nivolumab and ipilimumab in first line of treatment for inoperable pleural mesothelioma;Medical alphabet;2023-12-04

2. High Expression of SMO and GLI1 Genes with Poor Prognosis in Malignant Mesothelioma;BioMed Research International;2023-04-24

3. A prognostic score for patients with malignant pleural mesothelioma (MPM) receiving second-line immunotherapy or chemotherapy in the ETOP 9–15 PROMISE-meso phase III trial;Lung Cancer;2022-07

4. Active symptom control with or without oral vinorelbine in patients with relapsed malignant pleural mesothelioma (VIM): A randomised, phase 2 trial;eClinicalMedicine;2022-06

5. Splicing deregulation, microRNA and notch aberrations: fighting the three-headed dog to overcome drug resistance in malignant mesothelioma;Expert Review of Clinical Pharmacology;2022-03-04